Founded by Doctors. Focused on Patients.
Restoring cellular energy deficits at the root of heart disease and inborn errors of metabolism
At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors in metabolism.
Our lead program, ninerafaxstat, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. The pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.
Our team is uniquely positioned to execute our mission of translating our deep understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.
Our values provide guidance on how we act internally and with the external world to fulfill our mission of improving the lives of patients with limited or inadequate treatment options.